Effects of Ulinastatin on Myocardial Injury in Pediatric Patients Undergoing Living-Related Liver Transplantation

翁亦齐,喻文立,杜洪印,于洪丽,贾莉莉,吕丹,王永旺,于泳浩

DOI: https://doi.org/10.3760/cma.j.issn.0254-1416.2015.07.001

2015-01-01

Abstract:Objective To investigate the effects of ulinastatin on myocardial injury in pediatric patients undergoing living-related liver transplantation (LRLT).Methods Thirty pediatric patients of both sexes, aged 5-15 months, weighing 5-11 kg, with American Society of Anesthesiologists physical status Ⅲ or Ⅳ, scheduled for elective LRLT, were equally and randomly divided into either control group (group C) or ulinastatin group (group U) using a random number table.Ulinastatin 20 000 U/kg was diluted into 10 000 U/ml with normal saline, and it was then injected intravenously in 2 parts (1/2 was injected before skin incision;1/2 at 5 min before portal vein declamping) in group U.In group C, the equal volume of normal saline was given instead of ulinastatin.Immediately before skin incision (T0, baseline), at 30 min of anhepatic phase (T1), at 3 h of neohepatic phase (T2), and at the end of surgery (T3) , blood samples were taken from the central vein for determination of serum cardiac troponin I (cTnI) , lactate dehydrogenase (LDH) , and alpha-hydroxybutyrate dehydrogenase (α-HBDH) levels.The requirement for dopamine and occurrence of adverse cardiovascular events (hypertension or hypotension, myocardial ischemia and ventricular premature beat) were recorded during surgery.The changing rates of serum cTnI, LDH and α-HBDH levels were calculated at T1-3.Results Compared with group C, the serum cTnI, LDH and α-HBDH levels and the changing rates were significantly decreased at T2-3, and no significant changes were found in the incidence of adverse cardiovascular events and requirement for dopamine in group U.Conclusion Ulinastatin can attenuate the myocardial injury in pediatric patients undergoing LRLT.